Detailansicht

Wissensnetz

Person

Christoph Schmid

Arzt

Name	Christoph Schmid
Ort	Deutschland
Geschlecht	männlich
Akademischer Grad bzw. Titel	PD Dr. med.
Beruf	Arzt (charakteristischer Beruf) Facharzt
Weitere Angaben	Facharzt für Innere Medizin; Department of Internal Medicine II, Klinikum Augsburg
Datensatztyp	Person
GND-Nummer	1176729551
Datensatz-ID	1176729551
Beteiligt an alle anzeigen Continuously improving outcome over time after second allogeneic stem cell transplantation in relapsed acute myeloid leukemia: an EBMT registry analysis of 1540 patients Correction: Long term results of a prospective multicenter observational study on the use of anti-human T-lymphocyte immunoglobulin (ATLG) in unrelated donor transplantation (ATOS study) Continuously improving outcome over time after second allogeneic stem cell transplantation in relapsed acute myeloid leukemia: an EBMT registry analysis of 1540 patients Correction: Long term results of a prospective multicenter observational study on the use of anti-human T-lymphocyte immunoglobulin (ATLG) in unrelated donor transplantation (ATOS study) Correction: Real‑world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC‑FFM in ruxolitinib‑refractory acute graft‑versus‑host disease Dendritic/antigen presenting cell mediated provision of T-cell receptor gamma delta (TCRγδ) expressing cells contributes to improving antileukemic reactions ex vivo Long term results of a prospective multicenter obervational study on the use of anti-human T-lymphocyte immunoglobulin (ATLG) in unrelated donor transplantation (ATOS study) Long term results of a prospective multicenter observational study on the use of anti-human T-lymphocyte immunoglobulin (ATLG) in unrelated donor transplantation (ATOS study) Real-world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC-FFM in ruxolitinib-refractory acute graft-versus-host disease Autologous-allogeneic versus autologous tandem stem cell transplantation and maintenance therapy with thalidomide for multiple myeloma patients over 60 years of age: a prospective phase II study Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4 Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4 Impact of age and gender on lymphocyte subset counts in patients with COVID‐19 Real-world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC-FFM in ruxolitinib-refractory acute graft-versus-host disease Real-world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC-FFM in ruxolitinib-refractory acute graft-versus-host disease Relapse of acute myeloid leukemia after allogeneic stem cell transplantation: immune escape mechanisms and current implications for therapy Second haploidentical stem cell transplantation (HAPLO-SCT2) after relapse from a first HAPLO-SCT in acute leukaemia — a study on behalf of the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) Correction to: Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemia Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia P583: Patients at high risk of relapse post-transplant: a phase 1 study design with a novel treatment strategy using the estimand framework Predictive preoperative clinical score for patients with liver-only oligometastatic colorectal cancer The predictive value of the spinal instability neoplastic score (SINS) [Abstract] Transfusion‐refractory pancytopenia with MDS‐like morphologic alterations of the bone marrow in a 29‐year old man: A mimicry manifestation caused by scurvy Allogeneic stem cell transplantation for AML patients with RUNX1 mutation in first complete remission: a study on behalf of the acute leukemia working party of the EBMT Allogeneic stem cell transplantation for AML patients with RUNX1 mutation in first complete remission: a study on behalf of the acute leukemia working party of the EBMT Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia P 13. The added benefit of intraoperative neuromonitoring for resection of motor eloquent brain lesions: a comparative study Second- and third-generation tyrosine kinase inhibitors for Philadelphia-positive adult acute lymphoblastic leukemia relapsing post allogeneic stem cell transplantation—a registry study on behalf of the EBMT Acute Leukemia Working Party Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents—a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group Allogeneic stem cell transplantation for AML patients with RUNX1 mutation in first complete remission: a study on behalf of the ALWP of the EBMT Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents — a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents—a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group Biology-driven approaches to prevent and treat relapse of myeloid neoplasia after allogeneic hematopoietic stem cell transplantation Transplant outcomes for secondary acute myeloid leukemia: acute leukemia working party of the European Society for Blood and Bone Marrow Transplantation study ABO mismatching and haploidentical hematopoietic stem cell transplantation in acute myeloid leukemia: a report from the ALWP of the EBMT Graft-versus-leukemia effect following hematopoietic stem cell transplantation for leukemia Sequential intensified conditioning regimen allogeneic hematopoietic stem cell transplantation in adult patients with intermediate- or high-risk acute myeloid leukemia in complete remission: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation Allogeneic hematopoietic stem cell transplantation for secondary acute myeloid leukemia: a report from the Acute Leukemia Working Party of the EBMT High CD3+ and CD34+ peripheral blood stem cell grafts content is associated with increased risk of graft-versus-host disease without beneficial effect on disease control after reduced-intensity conditioning allogeneic transplantation from matched unrelated donors for acute myeloid leukemia: an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation Prediction of hematopoietic stem cell transplantation related mortality- lessons learned from the In-Silico approach: a European Society for Blood and Marrow Transplantation Acute Leukemia Working Party Data Mining Study RIC versus MAC UCBT in adults with AML: a report from Eurocord, the ALWP and the CTIWP of the EBMT T-cell-replete HLA-haploidentical transplantation using post-transplantation high-dose cyclophosphamide in high risk and advanced ALL: feasibility and early outcome Predictive limitations of hematopoietic stem cell transplantation associated mortality: a machine learning in-silico analysis of the EBMT - Acute Leukemia Working Party Registry Immunomodulation of blasts in AML-patients (pts) with clinically approved response modifiers to improve anti leukaemic T-cell reactivity: an ex vivo simulation of the clinical situation Proceedings from the National Cancer Institute’s Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part III. Prevention and treatment of relapse after allogeneic transplantation Comparison of allogeneic stem cell transplantation and non-transplant approaches in elderly patients with advanced myelodysplastic syndrome: optimal statistical approaches and a critical appraisal of clinical results using non-randomized data

Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

Katalog der Deutschen Nationalbibliothek

Christoph Schmid

Continuously improving outcome over time after second allogeneic stem cell transplantation in relapsed acute myeloid leukemia: an EBMT registry analysis of 1540 patients

Correction: Long term results of a prospective multicenter observational study on the use of anti-human T-lymphocyte immunoglobulin (ATLG) in unrelated donor transplantation (ATOS study)

Continuously improving outcome over time after second allogeneic stem cell transplantation in relapsed acute myeloid leukemia: an EBMT registry analysis of 1540 patients

Correction: Long term results of a prospective multicenter observational study on the use of anti-human T-lymphocyte immunoglobulin (ATLG) in unrelated donor transplantation (ATOS study)

Correction: Real‑world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC‑FFM in ruxolitinib‑refractory acute graft‑versus‑host disease

Dendritic/antigen presenting cell mediated provision of T-cell receptor gamma delta (TCRγδ) expressing cells contributes to improving antileukemic reactions ex vivo

Long term results of a prospective multicenter obervational study on the use of anti-human T-lymphocyte immunoglobulin (ATLG) in unrelated donor transplantation (ATOS study)

Long term results of a prospective multicenter observational study on the use of anti-human T-lymphocyte immunoglobulin (ATLG) in unrelated donor transplantation (ATOS study)

Real-world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC-FFM in ruxolitinib-refractory acute graft-versus-host disease

Autologous-allogeneic versus autologous tandem stem cell transplantation and maintenance therapy with thalidomide for multiple myeloma patients over 60 years of age: a prospective phase II study

Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4

Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4

Impact of age and gender on lymphocyte subset counts in patients with COVID‐19

Real-world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC-FFM in ruxolitinib-refractory acute graft-versus-host disease

Real-world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC-FFM in ruxolitinib-refractory acute graft-versus-host disease

Relapse of acute myeloid leukemia after allogeneic stem cell transplantation: immune escape mechanisms and current implications for therapy

Second haploidentical stem cell transplantation (HAPLO-SCT2) after relapse from a first HAPLO-SCT in acute leukaemia — a study on behalf of the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Correction to: Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemia

Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia

P583: Patients at high risk of relapse post-transplant: a phase 1 study design with a novel treatment strategy using the estimand framework

Predictive preoperative clinical score for patients with liver-only oligometastatic colorectal cancer

The predictive value of the spinal instability neoplastic score (SINS) [Abstract]

Transfusion‐refractory pancytopenia with MDS‐like morphologic alterations of the bone marrow in a 29‐year old man: A mimicry manifestation caused by scurvy

Allogeneic stem cell transplantation for AML patients with RUNX1 mutation in first complete remission: a study on behalf of the acute leukemia working party of the EBMT

Allogeneic stem cell transplantation for AML patients with RUNX1 mutation in first complete remission: a study on behalf of the acute leukemia working party of the EBMT

Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia

P 13. The added benefit of intraoperative neuromonitoring for resection of motor eloquent brain lesions: a comparative study

Second- and third-generation tyrosine kinase inhibitors for Philadelphia-positive adult acute lymphoblastic leukemia relapsing post allogeneic stem cell transplantation—a registry study on behalf of the EBMT Acute Leukemia Working Party

Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents—a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group

Allogeneic stem cell transplantation for AML patients with RUNX1 mutation in first complete remission: a study on behalf of the ALWP of the EBMT

Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents — a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group

Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents—a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group

Biology-driven approaches to prevent and treat relapse of myeloid neoplasia after allogeneic hematopoietic stem cell transplantation

Transplant outcomes for secondary acute myeloid leukemia: acute leukemia working party of the European Society for Blood and Bone Marrow Transplantation study

ABO mismatching and haploidentical hematopoietic stem cell transplantation in acute myeloid leukemia: a report from the ALWP of the EBMT

Graft-versus-leukemia effect following hematopoietic stem cell transplantation for leukemia

Sequential intensified conditioning regimen allogeneic hematopoietic stem cell transplantation in adult patients with intermediate- or high-risk acute myeloid leukemia in complete remission: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation

Allogeneic hematopoietic stem cell transplantation for secondary acute myeloid leukemia: a report from the Acute Leukemia Working Party of the EBMT

Prediction of hematopoietic stem cell transplantation related mortality- lessons learned from the In-Silico approach: a European Society for Blood and Marrow Transplantation Acute Leukemia Working Party Data Mining Study

RIC versus MAC UCBT in adults with AML: a report from Eurocord, the ALWP and the CTIWP of the EBMT

T-cell-replete HLA-haploidentical transplantation using post-transplantation high-dose cyclophosphamide in high risk and advanced ALL: feasibility and early outcome

Predictive limitations of hematopoietic stem cell transplantation associated mortality: a machine learning in-silico analysis of the EBMT - Acute Leukemia Working Party Registry

Immunomodulation of blasts in AML-patients (pts) with clinically approved response modifiers to improve anti leukaemic T-cell reactivity: an ex vivo simulation of the clinical situation

Proceedings from the National Cancer Institute’s Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part III. Prevention and treatment of relapse after allogeneic transplantation

Comparison of allogeneic stem cell transplantation and non-transplant approaches in elderly patients with advanced myelodysplastic syndrome: optimal statistical approaches and a critical appraisal of clinical results using non-randomized data